Dr. Strickler on the Exploration of Frontline Tucatinib/Trastuzumab in HER2+ CRC

Video

John H. Strickler, MD, discusses the investigation of frontline tucatinib plus trastuzumab in HER2-positive colorectal cancer.

John H. Strickler, MD, medical oncologist, Duke Cancer Center, Duke Health, discusses the investigation of frontline tucatinib (Tukysa) plus trastuzumab (Herceptin) in HER2-positive colorectal cancer (CRC).

Data from the phase 2 MOUNTAINEER trial (NCT03043313) showed that tucatinib plus trastuzumab elicited clinically meaningful and durable responses in patients with previously treated metastatic HER2-positive CRC. Now investigators want to explore whether this combination be a viable first-line option for this patient population, Strickler explains.

The ongoing phase 3 MOUNTAINEER-03 trial (NCT05253651) is exploring the combination of tucatinib and trastuzumab plus modified fluoropyrimidine, leucovorin, and oxaliplatin (mFOLFOX6) vs standard of care as a frontline treatment for patients with HER2-positive CRC, Strickler says.

Other ongoing trials are examining anti-HER2 regimens vs anti-EGFR regimens in the second-line setting and beyond to investigate if there is still a role for anti-EGFR therapies in patients with HER2-positive CRC, Strickler adds. Preclinical data have suggested that HER2 expression drives resistance to anti-EGFR therapy, though this has yet to be seen in a prospective, randomized trial, Strickler concludes.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
A panel of 6 experts on colorectal cancer
A panel of 6 experts on colorectal cancer